Top

Published in:

Open Access 01-05-2022 | Glioblastoma | Original Article

Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma

Authors: Cas S. Dejonckheere, Alexander M. C. Böhner, David Koch, Leonard C. Schmeel, Ulrich Herrlinger, Hartmut Vatter, Matthias Schneider, Patrick Schuss, Frank A. Giordano, Mümtaz A. Köksal

Published in: Strahlentherapie und Onkologie | Issue 5/2022

Abstract

Background and purpose

Primary gliosarcoma (GS) is a rare variant of IDH-wildtype glioblastoma multiforme. We performed a single-center analysis to identify prognostic factors.

Patients and methods

We analyzed the records of 26 patients newly diagnosed with primary WHO grade IV GS. Factors of interest were clinical and treatment data, as well as molecular markers, time to recurrence, and time to death.

Results

Median follow-up was 9 months (range 5–21 months). Gross total resection did not lead to improved survival, most likely due to the relatively small sample size. Low symptom burden at the time of diagnosis was associated with longer PFS (P = 0.023) and OS (P = 0.018). Median OS in the entire cohort was 12 months. Neither MGMT promoter hypermethylation nor adjuvant temozolomide therapy influenced survival, consistent with some previous reports.

Conclusion

In this retrospective study, patients exhibiting low symptom burden at diagnosis showed improved survival. None of the other factors analyzed were associated with an altered outcome.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11:183–191. https://doi.org/10.1215/15228517-2008-076CrossRefPubMedPubMedCentral

Heesters M, Molenaar W, Go GK (2003) Radiotherapy in supratentorial gliomas. A study of 821 cases. Strahlenther Onkol 179:606–614. https://doi.org/10.1007/s00066-003-1098-9CrossRefPubMed

McAleer MF, Brown PD (2015) Therapeutic management of gliosarcoma in the temozolomide era. CNS Oncol 4:171–178. https://doi.org/10.2217/cns.14.61CrossRefPubMedPubMedCentral

Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS et al (2015) Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 125:401–410. https://doi.org/10.1007/s11060-015-1930-yCrossRefPubMedPubMedCentral

Smith DR, Wu C‑C, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB et al (2018) Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. J Neurooncol 137:303–311. https://doi.org/10.1007/s11060-017-2718-zCrossRefPubMed

Frandsen S, Broholm H, Larsen VA, Grunnet K, Møller S, Poulsen HS et al (2019) Clinical characteristics of gliosarcoma and outcomes from standardized treatment relative to conventional glioblastoma. Front Oncol 9:1425. https://doi.org/10.3389/fonc.2019.01425CrossRefPubMedPubMedCentral

Moon SK, Kim EJ, Choi WS, Ryu CW, Park BJ, Lee J (2010) Gliosarcoma of the cerebellar hemisphere: a case report and review of the literature. Korean J Radiol 11:566–570. https://doi.org/10.3348/kjr.2010.11.5.566CrossRefPubMedPubMedCentral

Singh G, Mallick S, Sharma V, Joshi N, Purkait S, Jha P et al (2012) A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. Neuropathology 32:534–542. https://doi.org/10.1111/j.1440-1789.2012.01297.xCrossRefPubMed

10.

Feigin IH, Gross SW (1955) Sarcoma arising in glioblastoma of the brain. Am J Pathol 31:633–653PubMedPubMedCentral

11.

de Macedo Filho LJM, Barreto EG, Martins PLB, Filho ENS, Gerson G, de Albuquerque LAF (2020) IDH1-mutant primary intraventricular gliosarcoma: case report and systematic review of a rare location and molecular profile. Surg Neurol Int 11:372. https://doi.org/10.25259/SNI_586_2020CrossRefPubMedPubMedCentral

12.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

13.

Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L et al (2005) Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181:372–377. https://doi.org/10.1007/s00066-005-1359-xCrossRefPubMed

14.

Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH et al (2018) Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen: acute toxicity in pediatric high-grade glioma patients. Strahlenther Onkol 194:215–224. https://doi.org/10.1007/s00066-017-1218-6CrossRefPubMed

15.

Morantz RA, Feigin I, Ransohoff J 3rd (1976) Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg 45:398–408. https://doi.org/10.3171/jns.1976.45.4.0398CrossRefPubMed

16.

Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313–320. https://doi.org/10.1007/s11060-009-9973-6CrossRefPubMed

17.

Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS et al (2019) Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. J Neurooncol 144:53–63. https://doi.org/10.1007/s11060-019-03215-xCrossRefPubMedPubMedCentral

18.

Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J et al (2018) Patterns of care and outcomes in gliosarcoma: an analysis of the national cancer database. J Neurosurg 128:1133–1138. https://doi.org/10.3171/2016.12.JNS162291CrossRefPubMed

19.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB et al (2017) An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. Neuro Oncol 19:669–677. https://doi.org/10.1093/neuonc/now208CrossRefPubMed

20.

Jin MC, Liu EK, Shi S, Gibbs IC, Thomas R, Recht L et al (2020) Evaluating surgical resection extent and adjuvant therapy in the management of gliosarcoma. Front Oncol 10:337. https://doi.org/10.3389/fonc.2020.00337CrossRefPubMedPubMedCentral

21.

Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y (2016) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. J Neurooncol 127:355–362. https://doi.org/10.1007/s11060-015-2046-0CrossRefPubMed

22.

Kang S‑H, Park K‑J, Kim C‑Y, Yu MO, Park C‑K, Park S‑H et al (2011) O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 101:477–486. https://doi.org/10.1007/s11060-010-0267-9CrossRefPubMed

23.

Pierscianek D, Ahmadipour Y, Michel A, Rauschenbach L, Darkwah Oppong M, Deuschl C et al (2021) Demographic, radiographic, molecular and clinical characteristics of primary gliosarcoma and differences to glioblastoma. Clin Neurol Neurosurg 200:106348. https://doi.org/10.1016/j.clineuro.2020.106348CrossRefPubMed

24.

Jain A, Correia J, Schweder P, McMahon A, Merola J, Aspoas R (2017) Analysis of outcomes of multidisciplinary management of gliosarcoma: a single-center study, 2000–2013. World Neurosurg 106:30–36. https://doi.org/10.1016/j.wneu.2017.06.073CrossRefPubMed

25.

Ahmed FI, Abdullah KG, Durgin J, Salinas RD, O’Rourke DM, Brem S (2019) Evaluating the association between the extent of resection and survival in gliosarcoma. Cureus 11:e4374. https://doi.org/10.7759/cureus.4374CrossRefPubMedPubMedCentral

26.

Feng S‑S, Li H‑B, Fan F, Li J, Cao H, Xia Z‑W et al (2019) Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis. Sci Rep 9:10744. https://doi.org/10.1038/s41598-019-47211-7CrossRefPubMedPubMedCentral

27.

Huang Q, Li F, Chen Y, Hong F, Wang H, Chen J (2020) Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a surveillance, epidemiology, and end results (SEER) analysis from 2004 to 2015. Br J Neurosurg 34:161–167. https://doi.org/10.1080/02688697.2019.1699903CrossRefPubMed

28.

Ma R, Alexe D‑M, Pereira EA (2020) Primary gliosarcoma: epidemiology, clinical presentation, management, and survival. J Neurosurg Sci 64:341–346. https://doi.org/10.23736/S0390-5616.17.04077-2CrossRefPubMed

29.

Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112:83–89. https://doi.org/10.1007/s11060-012-1029-7CrossRefPubMed

30.

Peckham ME, Osborn AG, Palmer CA, Tsai A, Salzman KL (2019) Gliosarcoma: neuroimaging and immunohistochemical findings. J Neuroimaging 29:126–132. https://doi.org/10.1111/jon.12565CrossRefPubMed

31.

Yi X, Cao H, Tang H, Gong G, Hu Z, Liao W et al (2019) Gliosarcoma: a clinical and radiological analysis of 48 cases. Eur Radiol 29:429–438. https://doi.org/10.1007/s00330-018-5398-yCrossRefPubMed

32.

Lee D, Kang SY, Suh Y‑L, Jeong JY, Lee J‑I, Nam D‑H (2012) Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107:643–650. https://doi.org/10.1007/s11060-011-0790-3CrossRefPubMed

33.

Rath GK, Sharma DN, Mallick S, Gandhi AK, Joshi NP, Haresh KP et al (2015) Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: a single institutional analysis of 27 cases. Indian J Cancer 52:599–603. https://doi.org/10.4103/0019-509X.178407CrossRefPubMed

34.

Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S et al (2016) Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J Neurooncol 128:341–348. https://doi.org/10.1007/s11060-016-2117-xCrossRefPubMed

35.

Castelli J, Feuvret L, Haoming QC, Biau J, Jouglar E, Berger A et al (2016) Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. J Neurooncol 129:85–92. https://doi.org/10.1007/s11060-016-2142-9CrossRefPubMed

Title: Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma
Authors: Cas S. Dejonckheere
Alexander M. C. Böhner
David Koch
Leonard C. Schmeel
Ulrich Herrlinger
Hartmut Vatter
Matthias Schneider
Patrick Schuss
Frank A. Giordano
Mümtaz A. Köksal
Publication date: 01-05-2022
Publisher: Springer Berlin Heidelberg
Keywords: Glioblastoma
Glioblastoma
Radiotherapy
Glioblastoma
Published in: Strahlentherapie und Onkologie / Issue 5/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-021-01884-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2022

Körperstereotaktische Bestrahlung als „Erstlinientherapie“ des oligometastasierten Nierenzellkarzinoms

Survival outcomes, hematologic complications and growth impairment after sequential chemoradiotherapy in intracranial NGGCTs: a retrospective study

Unerwünschte Ereignisse bei Patienten unter Immuntherapie nach Strahlentherapie – gepoolte Analyse von Studien aus der Datenbank der US Food and Drug Administration

Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis—a safety analysis and validation of the EANO-ESMO classification

Deutlicher Überlebensvorteil durch simultane Radio- und Chemotherapie: Erkenntnisse aus einer chinesischen Phase-III-Studie bei älteren Patienten mit Ösophaguskarzinom

Single-isocenter stereotactic non-coplanar arc treatment of 200 patients with brain metastases: multileaf collimator size and setup uncertainties